Novartis Halts 8 CAR-T Trials After 3 Patient Deaths
NVS Novartis AG ADR
$152.06 -1.14%
View chart & analysis → - 1Novartis (NVS) has halted eight clinical trials of its experimental CAR-T therapy.
- 2Three patient deaths were confirmed in late August across trials for autoimmune and neurological diseases.
- 3An investigation into the link between the deaths and the drug continues, also affecting Bristol Myers Squibb and others.
This 3-line summary is compiled from the report below.
Barrons.com +1 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이, 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다